Trials / Completed
CompletedNCT00452257
A Study of Enzastaurin in Patients With Leukemia
A Phase 1b Pharmacokinetic-Pharmacodynamic-Pharmacogenomic Study of Enzastaurin in Patients With B-Cell Chronic Lymphocytic Leukemia (B-CLL)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to see if enzastaurin affects the pGSK3 beta level in B-cell chronic lymphocytic leukemia (B-CLL) cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | enzastaurin | 1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2007-03-27
- Last updated
- 2009-03-19
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00452257. Inclusion in this directory is not an endorsement.